ETV3L Inhibitors
ETV3L inhibitors encompass a variety of chemical compounds that directly or indirectly lead to the suppression of ETV3L's functional activities within diverse biological pathways. For example, PD 0332991, a specific inhibitor of CDK4/6, disrupts cell cycle progression, which is a process where ETV3L plays a regulatory role; thus, its inhibition effectively diminishes ETV3L's role in cell proliferation. Similarly, ETV3L's functions in cellular growth and metabolism, potentially regulated by the mTOR pathway, are targetedby Rapamycin, an mTOR inhibitor that leads to the suppression of these ETV3L-mediated processes. Trichostatin A, which alters chromatin structure and consequently gene expression, can modify the transcriptional landscape that ETV3L is a part of, resulting in reduced ETV3L activity. Additionally, small molecule inhibitors like LY 294002 and SP600125 target the PI3K/AKT and JNK pathways, respectively, which are critical for survival, growth, and stress responses where ETV3L might be implicated; their inhibition can thus diminish ETV3L activity in these contexts.
In the realm of stress and inflammatory signaling, compounds such as SB 203580 and PD 98059, which respectively inhibit p38 MAPK and MEK1/2, may result in decreased ETV3L activity by impacting the pathways it is associated with. The MEK inhibitor U0126 operates similarly, potentially reducing ETV3L's involvement in the MAPK/ERK signaling cascade. Furthermore, WZB117, by impeding GLUT1-mediated glucose uptake, can attenuate the metabolic functions in which ETV3L is active, while Bortezomib's proteasome inhibition could alter protein turnover, affecting ETV3L's regulatory roles. Dasatinib's inhibition of tyrosine kinase signaling, which ETV3L may influence through its transcriptional regulation, leads to a decrease in ETV3L activity. Lastly, Thalidomide's modulation of cytokine expression can indirectly suppress the immune-related functions of ETV3L, showcasing the diverse biochemical mechanisms by which these inhibitors collectively contribute to the reduction of ETV3L's functional activities within cells.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A CDK4/6 inhibitor that disrupts cell cycle progression. ETV3L is involved in the regulation of the cell cycle, and by inhibiting CDK4/6, PD 0332991 would lead to cell cycle arrest, thereby diminishing the functional activity of ETV3L in cell proliferation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor that interrupts the mTOR signaling pathway. Since ETV3L is implicated in cellular growth and metabolism processes regulated by mTOR, Rapamycin would decrease these ETV3L-mediated functions by inhibiting the mTOR pathway. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
A histone deacetylase inhibitor that alters chromatin structure and gene expression. By affecting transcriptional regulation, Trichostatin A can lead to a diminished activity of ETV3L by altering the transcriptional landscape in which ETV3L operates. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3K inhibitor that impedes the PI3K/AKT pathway, central to many cellular processes including survival and growth. Inhibition of this pathway would likely lead to decreased activity of ETV3L since PI3K/AKT can impact transcription factors and genes associated with ETV3L functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor that impedes the JNK signaling pathway, which is involved in stress responses and apoptosis. By inhibiting JNK, SP600125 could reduce the functional activity of ETV3L if ETV3L is involved in cellular response to stress and apoptotic processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A p38 MAPK inhibitor that blocks the p38 MAPK signaling pathway involved in inflammation and cell differentiation. ETV3L, being a transcriptional regulator, may be influenced by this pathway, and inhibition by SB 203580 would lead to diminished ETV3L activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor that blocks MEK1/2, key enzymes in the MAPK/ERK pathway. ETV3L could be involved in gene expression regulated by this pathway, and therefore PD 98059 would inhibit ETV3L by diminishing the ERK signaling that ETV3L might impact. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Another MEK inhibitor with similar effects as PD98059, leading to the inhibition of the MAPK/ERK pathway. This would likely diminish the activity of ETV3L by impeding the signaling cascade that ETV3L is potentially involved in. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
A GLUT1 inhibitor that hinders glucose uptake in cells. As ETV3L is related to cellular metabolism, the inhibition of glucose transport by WZB117 would decrease the metabolic functions where ETV3L is active. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that impedes the degradation of proteins, affecting numerous cellular processes including the cell cycle and apoptosis. This could lead to diminished activity of ETV3L by altering the turnover of proteins that regulate ETV3L functions. | ||||||